经皮椎体成形术治疗多发性骨髓瘤椎体病变
摘要
多发性骨髓瘤是血液系统最常见的恶性肿瘤之,而多发性骨髓瘤骨病会引起溶骨性病变及广泛的骨质疏松,其中椎体骨折是较严重的甚至危及生命的损害之一。超过半数的患者是因为出现了骨折、骨痛等症状来医院就诊,初诊时即已存在骨质破坏。化疗能有效抑制单克隆免疫球蛋白的恶性增生,但对于已经发生不可逆的骨质破坏却无能为力。对于那些存在椎体骨折,尤其是椎体压缩性骨折的患者,除去原发病,脊髓失去保护也时刻威胁着他们的生命状态。
出处
《江苏医药》
CAS
北大核心
2013年第23期2920-2921,共2页
Jiangsu Medical Journal
基金
江苏省医学重点学科(2011-12)
参考文献4
-
1Galibert P, Deramond H, Rosat P, et al. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty[J]. Neurochirurgie, 1987,33 (2) : 166-168.
-
2Bosnjakovi P, Risti S, Mrvi M, et al. Management of painful spinal lesions caused by multiple myeloma using pereutaneous acrylic cement inj ection[J]. Acta Chir Iugosl, 2009,56 (4) : 153- 158.
-
3Yang Z,Tan J,Xu Y,et al. Treatment of MM-associated spinal fracture with percutaneous vertebroplasty(PVP) and chemo- therapy[J]. Eur Spine J, 2012,21 (5) : 912-919.
-
4谢振卿,李斯丹,徐燕,邱录贵.多发性骨髓瘤骨病的发病机制和靶向治疗研究进展[J].中华血液学杂志,2012,33(3):247-249. 被引量:9
二级参考文献28
-
1Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res, 2011, 17 : 1225-1233.
-
2Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma, 2010, 51 : 213-220.
-
3Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in on- cology. Clin Cancer Res, 2010, 16: 4084-4093.
-
4Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep, 2007, 5: 98-104.
-
5Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by nmhiple myeloma ceils. Blood, 2002, 100: 3002-3007.
-
6Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts snr- viva/in multiple myeloma: proposal for a novel prognostic index. Blood, 2003, 102: 1064-1069.
-
7Jakob C, Goerke A, Terpos E, et al. Serum levels of total-RANKL in multiple myeloma. Clin Lymphoma Myeloma, 2009, 9: 430- 435.
-
8Oyajobi BO, Franehin G, Williams PJ, et al. Dual effects of mac- rophage inflammatory protein-l alpha on osteolysis and tumor bur- den in the murine 5TGM1 model of myelmna bone disease. Blood, 2003, 102: 311-319.
-
9Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha (MIP-I alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) ceils. Blood, 2003, 101 : 3633-2646.
-
10Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-lalpha are associated with in- creased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer ltes, 2005, 65: 1700-1709.
共引文献8
-
1杨俊超,杨一飞,李丽,张瑞英,于艳芳,申娜,周晨光.沙利度胺联合川芎嗪及改良预激化疗方案治疗难治性急性白血病25例疗效分析[J].内科急危重症杂志,2013,19(5):301-302. 被引量:2
-
2李增怀.硼替佐米结合地塞米松对多发性骨髓瘤骨病患者生化指标的影响[J].中国生化药物杂志,2015,35(4):138-140. 被引量:16
-
3王思力,苏蕊,黄耘,方志鸿.双膦酸盐类药物治疗多发性骨髓瘤患者骨病的临床疗效[J].中国老年学杂志,2018,38(2):340-342. 被引量:3
-
4刘光美.硼替佐米联合地塞米松治疗多发性骨髓瘤的疗效分析[J].中外医疗,2017,36(32):133-134. 被引量:5
-
5马荣军,朱尊民,袁晓莉,姜丽,杨世伟,杨靖,王臻,雷平冲,孙恺,郭建民,张琳,张茵.TRACP-5b、PINP及维生素D3在骨髓瘤骨病患者治疗前后的变化及意义[J].中华血液学杂志,2018,39(8):685-687. 被引量:9
-
6贾新勇,郭改玲,王秋平,申燕.N-Cadherin、sCD40水平变化与多发性骨髓瘤患者临床分期的关联性分析[J].实验与检验医学,2018,36(6):853-855. 被引量:3
-
7葛岩,丁香梅,高凌霞.硼替佐米联合地塞米松治疗多发性骨髓瘤的疗效及安全性分析[J].医学理论与实践,2020,33(1):65-66. 被引量:6
-
8苏静.miR-199a-5p介导的lncRNA ANRIL通过调节HIF-1α促进多发性骨髓瘤的恶性增殖[J].国际检验医学杂志,2022,43(19):2357-2363. 被引量:1
-
1庄正陵,刘瀚霖,青光恒,赵传军,闫学军.经皮椎体成形术治疗椎体血管瘤[J].生物骨科材料与临床研究,2009,6(4):8-10. 被引量:3
-
2雷成刚.经皮椎体成形术治疗骨质疏松的椎体压缩性骨折[J].临床外科杂志,2011,19(9):648-650. 被引量:3
-
3高文革,刘玉臣,于镜贺.椎体嗜酸性肉芽肿5例分析[J].中国冶金工业医学杂志,2006,23(4):520-520.
-
4邢小平,孟迅吾,顾锋,白耀,余卫,解毓章,葛昌文.四例以骨质疏松、椎体骨折为特征的儿童急性白血病[J].中华血液学杂志,1995,16(11):599-600. 被引量:1
-
5黄海汛,范海泉,陈铭,杨帆,刘江川.经皮椎体成形术治疗多发性骨髓瘤的临床疗效[J].脊柱外科杂志,2014,12(2):100-102. 被引量:4
-
6郭鸿平.磁共振扩散加权序列成像对良恶性椎体骨折鉴别诊断的研究[J].基层医学论坛,2017,21(5):603-604. 被引量:5
-
7李海清,代荣琴.以椎体骨折为首发的急性早幼粒细胞白血病1例[J].国际检验医学杂志,2013,34(11):1487-1487.
-
8孙昆昆,沈丹华.椎体肿物[J].中华病理学杂志,2009,38(9):628-629. 被引量:1
-
9王松海.骨质疏松或骨转移瘤致椎体压缩性骨折的MRI鉴别[J].实用癌症杂志,2014,29(2):202-204. 被引量:10
-
10庄文越,张吉林.多发性骨髓瘤骨病的机制与治疗[J].北华大学学报(自然科学版),2009,10(6):507-512. 被引量:4